314 completed. 314 Phase 1, 29 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 314 | Completed 314 |
| Phase 2 | 29 | Completed 29 |
Follow Asthma: new trials by email Literature Review of Asthma trials Research Report on Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma Budesonide/formoterol fumarate Aerosphere, Budesonide/formoterol fumarate pMDI - Asthma | Phase 1 | Completed | AstraZeneca | 16 | 2026-03-05 | 2026-07-15 |
| Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers AJU-R713, R713R - Bronchial Asthma, Perennial Allergic Rhinitis | Phase 1 | Completed | AJU Pharm Co., Ltd. | 62 | 2025-12-12 | 2026-09-18 |
| A Clinical Study to Evaluate SM17 in Healthy Participants SM17, SM17 placebo - Atopic Dermatitis, Asthma | Phase 1 | Completed | SinoMab BioScience Ltd | 30 | 2025-10-14 | 2026-04-06 |
| A Study of Inhaled AZD8630 in Adolescents With Asthma AZD8630, Dry powder inhaler - Asthma | Phase 1 | Completed | AstraZeneca | 10 | 2025-06-11 | 2025-10-14 |
| A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants Placebo, IBI3002 - Asthma | Phase 1 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 44 | 2025-05-14 | 2026-06-09 |
| A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma HFA-152A propellant, HFA-134A propellant - Asthma | Phase 1 | Completed | GlaxoSmithKline | 20 | 2025-03-11 | 2026-08-21 |
| Study to Evaluate the Pharmacokinetics and Pharmacodynamics of AZD4604 Given Via the Turbuhaler® Device in Adults With Mild Asthma. AZD4604, Placebo, Genuair - Asthma | Phase 1 | Completed | AstraZeneca | 28 | 2025-02-27 | 2025-06-05 |
| A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma AZD8630, Placebo, Saphira device - Asthma | Phase 1 | Completed | AstraZeneca | 24 | 2025-01-28 | 2025-10-03 |
| A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA - Healthy Participants | Phase 1 | Completed | AstraZeneca | 105 | 2025-01-23 | 2025-06-05 |
| A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants. AZD8630 (test formulation) via test inhaler, AZD8630 (reference formulation) via Monodose inhaler, Test inhaler - Healthy Participants | Phase 1 | Completed | AstraZeneca | 32 | 2024-08-06 | 2024-10-17 |
| Study of the Effect of HFA-152a and HFA-134a Propellants on Mucociliary Clearance in Healthy Participants HFA-152a, HFA-134a, Radiolabeled saline solution - Asthma | Phase 1 | Completed | GlaxoSmithKline | 24 | 2024-07-29 | 2026-04-14 |
| Safety, Tolerability, and Pharmacokinetics of PA9159 Inhalation Aerosol in Healthy Adult Subjects PA9159 Inhalation aerosol, 60 μg one day treatment, PA9159 Inhalation aerosol, 120 μg one day treatment, PA9159 Inhalation aerosol, 240 μg one day treatment - Bronchial Asthma | Phase 1 | Completed | Anhui Palo Alto Pharmaceuticals, Inc. | 40 | 2024-07-22 | 2025-12-30 |
| A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive Salbutamol HFA-152a, Salbutamol HFA-134a - Asthma, Healthy Participants | Phase 1 | Completed | GlaxoSmithKline | 60 | 2024-06-04 | 2026-01-12 |
| Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old TEV-56248, Fp MDPI - Asthma | Phase 1 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 30 | 2024-05-16 | 2026-08-04 |
| A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers Tozorakimab - Healthy Participants | Phase 1 | Completed | AstraZeneca | 46 | 2024-04-08 | 2024-09-19 |
| Effect of Halotherapy in Children With Asthma Halotherapy (Salt Therapy) - Therapy, Oxygen Inhalation | Phase 1 | Completed | Igdir University | 70 | 2024-03-06 | 2024-08-02 |
| A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics IBI3002, Placebo - Healthy Participants, Asthma | Phase 1 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 52 | 2024-02-26 | 2025-11-21 |
| An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604 AZD4604 Inhalation Powder, 1 mg, [14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL), [14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq) - Asthma | Phase 1 | Completed | AstraZeneca | 8 | 2024-02-16 | 2024-05-29 |
| Bioequivalence Study of Budesonide/Formoterol Inhalation Powder in Healthy Participants Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Test), Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Reference) - Asthma, Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | Completed | Shanghai Xin Huanghe Pharmaceutical Co., Ltd. | 30 | 2024-01-13 | 2026-09-04 |
| A Single-Arm Phase Ic Clinical Study of XKH001 Injection in Patients With Allergic Asthma After Multiple Doses XKH001 Injection - Asthma Patients | Phase 1 | Completed | Zhejiang Kanova Biopharmaceutical Co., LTD | 12 | 2023-12-26 | 2025-07-17 |
Showing 20 of 314. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (39) · Hypersensitivity (17) · Rhinitis, Allergic, Perennial (8) · Dermatitis, Atopic (6) · Inflammation (6) · Rhinitis, Allergic (5) · Cystic Fibrosis (3) · Obesity (3) · Respiratory Aspiration (3) · Aspergillosis (2) · Asthma, Exercise-Induced (2) · Emphysema (2) · Respiratory Sounds (2) · Rhinitis, Allergic, Seasonal (2)
Hypersensitivity, Immediate (314) · Respiratory Hypersensitivity (314) · Bronchial Diseases (313) · Immune System Diseases (313) · Respiratory Tract Diseases (313) · Lung Diseases, Obstructive (312) · Lung Diseases (311) · Hypersensitivity (297) · Pathological Conditions, Signs and Symptoms (54) · Pathologic Processes (48) · Chronic Disease (39) · Disease Attributes (39) · Nose Diseases (14) · Otorhinolaryngologic Diseases (14) · Rhinitis (13)
Budesonide (23) · Fluticasone (11) · montelukast (11) · Charcoal (10) · Formoterol Fumarate (8) · Albuterol (7) · Budesonide, Formoterol Fumarate Drug Combination (6) · Fluticasone-Salmeterol Drug Combination (6) · Salmeterol Xinafoate (6) · fluticasone furoate (6) · Injections, Subcutaneous (4) · Prednisone (4) · tezepelumab (4) · vilanterol (4) · 3-(3-tert-butylsulfanyl-1-(4-(6-ethoxypyridin-3-yl)benzyl)-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl)-2,2-dimethylpropionic acid (3)
GlaxoSmithKline (56) · AstraZeneca (35) · Orion Corporation, Orion Pharma (13) · Merck Sharp & Dohme LLC (9) · Chiesi Farmaceutici S.p.A. (8) · Boehringer Ingelheim (7) · MedImmune LLC (7) · University of North Carolina, Chapel Hill (7) · Intech Biopharm Ltd. (6) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Novartis Pharmaceuticals (5) · Teva Branded Pharmaceutical Products R&D, Inc. (5) · Amgen (3) · Hal C Charles (3) · Indiana University (3)
United States (95) · United Kingdom (68) · Germany (40) · Australia (24) · China (22) · Finland (10) · New Zealand (9) · Canada (8) · Belgium (7) · Netherlands (6) · Taiwan (5) · Poland (4) · South Korea (4) · Russia (3) · Spain (3)
Robert Wood, MD (5) · Cecil Charles, PhD (3) · David B Peden, MD, MS (3) · Leena Mattila, MD, PhD (3) · Ulla Sairanen, MSc (3) · Andrew D Luster, M.D., Ph.D. (2)
PMID 24184147, PMID 32907575, PMID 40185989, PMID 11163535, PMID 11728816, PMID 17717202, PMID 18244953, PMID 19446146, PMID 19717725, PMID 19821718, PMID 19944580, PMID 20976161, PMID 21057005, PMID 21639872, PMID 21729182, PMID 22544892, PMID 22616628, PMID 22955319, PMID 22989372, PMID 23102735, PMID 23176889, PMID 23706713, PMID 24093504, PMID 24568613, PMID 24846652, PMID 25485197, PMID 25614148, PMID 25700806, PMID 26830468, PMID 27127998, PMID 27464582, PMID 27849125, PMID 28193704, PMID 28455782, PMID 28734844, PMID 28933971, PMID 29642282, PMID 29856004, PMID 29989511, PMID 30146344, PMID 31391226, PMID 31539289, PMID 31597083, PMID 31714895, PMID 32415720, PMID 32423275, PMID 32865454, PMID 32907566, PMID 32907576, PMID 33380362
2016 (8), 2014 (5), 2015 (5), 2019 (4), 2018 (3), P01AT002620 (2), P01HL158507 (2), U19AI095261 (2), 2009 (1), 2017 (1), 2023 (1), P01AT002647 (1), P50AT002782 (1), U19AI077437 (1)